Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, Shackel NA, McCaughan GW, Strasser SI. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World J Gastroenterol 2017; 23(15): 2763-2770 [PMID: 28487614 DOI: 10.3748/wjg.v23.i15.2763]
Corresponding Author of This Article
Dr. Mohsen Waled, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital Missenden, Rd Camperdown, Sydney NSW 2050, Australia. wmoh6298@uni.sydney.edu.au
Research Domain of This Article
Allergy
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2017; 23(15): 2763-2770 Published online Apr 21, 2017. doi: 10.3748/wjg.v23.i15.2763
Table 1 Etiology of liver disease n (%)
HBV
HCV
Non-viral
No patients
467 (29)
299 (45)
268 (26)
Etiology of non-viral liver disease
Alcoholic liver disease
144 (53.7)
NAFLD
85 (31.7)
Haemochromatosis
18 (6.7)
Primary sclerosing cholangitis
6 (2.3)
Primary biliary cirrhosis
8 (3)
Alpha-1 antitrypsin deficiency
3 (1.1)
Congenital hepatic fibrosis
1 (0.4)
Autoimmune hepatitis
3 (1.1)
Table 2 Patient characteristics according to etiology of liver disease
HBV
HCV
Non-viral
P value
Male (%)
84.3
79.2
80.6
< 0.250
Ethnicity (%)
Caucasian
16.4
73.4
87.3
< 0.001
Asian
75.8
18.2
9.0
< 0.001
Middle Eastern
3.7
7.1
2.2
< 0.001
Polynesian
2.3
0.6
0.0
< 0.001
Aboriginal
0.3
0.2
1.1
< 0.001
African
1.3
0.4
0.4
< 0.001
Median age (95%CI)
57 (55-59)
55 (54-56)
64 (63-65)
< 0.001
Screening program (%)
71
84
71
< 0.001
Median AFP (95%CI)
60 (40-98)
21 (16-28)
9 (6-19)
< 0.001
Table 3 Severity of liver disease and cirrhosis at hepatocellular carcinoma diagnosis
HBV (%)
HCV (%)
Non-viral (%)
P value
Child-Pugh score
A
58.6
53.9
41.9
< 0.001
B
13.7
29.0
28.3
< 0.001
C
4.9
14.4
17.1
< 0.001
Non-cirrhotic
22.8
2.6
12.8
< 0.001
Median MELD score
6.4
8.2
8.8
< 0.001
Cirrhosis
77.8
97.4
87.2
< 0.001
Table 4 Tumor characteristics and vascular invasion
HBV (%)
HCV (%)
Non-viral (%)
P value
Size of dominant lesion
< 1 cm
1.3
2.8
2.6
< 0.001
1-3 cm
34.4
46.5
32.1
< 0.001
3-5 cm
22.4
23.8
20.5
< 0.001
> 5 cm
32.0
18.0
34.0
< 0.001
Unknown
10.0
9.2
10.4
< 0.001
Tumor extent > 50%
12.4
4.2
12.5
< 0.001
Vascular invasion
10.4
6.7
12.3
< 0.020
Table 5 Treatment modalities used for patients with hepatocellular carcinoma
Treatment
Hepatitis B (%)
Hepatitis C (%)
Non-viral (%)
P value
TACE
44.5
45.4
39.2
0.099
Ablation
11.1
18.4
10.8
0.011
Resection
24.4
8.8
13.1
< 0.001
Transplant
13.4
21.4
12.3
0.001
Sorafenib
5
4.1
4.1
0.098
Supportive care
21
20
29
< 0.02
Table 6 Multivariate analysis for predictors of survival
Variable
Reference
HR
95%CI for HR
P value
Hepatitis B
Non-viral
0.900
0.674-1.200
0.472
Hepatitis C
Non-viral
1.086
0.841-1.401
0.527
Age at presentation
Years
1.009
1.000-1.018
0.062
Non-cirrhotic
Child Pugh C
0.267
0.165-0.433
< 0.001
Child Pugh A
Child Pugh C
0.403
0.287-0.566
< 0.001
Child Pugh B
Child Pugh C
0.705
0.501-0.992
0.045
Gender
Male
0.978
0.748-1.280
0.874
MELD
MELD score
1.016
0.999-1.033
0.072
Resection
Yes
2.212
1.434-3.413
< 0.001
Dominant lesion < 1 cm
Dominant lesion > 5 cm
0.375
0.156-0.898
0.028
Dominant lesion 1-3 cm
Dominant lesion > 5 cm
0.527
0.394-0.704
< 0.001
Dominant lesion 3-5 cm
Dominant lesion > 5 cm
0.740
0.550-0.995
0.046
Sorafenib
Yes
1.118
0.688-1.817
0.652
TACE
Yes
1.371
0.938-2.004
0.103
Transplant
Yes
8.486
5.185-13.889
< 0.001
Tumor extent < 50%
Tumor extent > 50%
0.690
0.476-1.000
0.050
Vascular invasion
Yes
0.555
0.393-0.784
0.001
Citation: Mohsen W, Rodov M, Prakoso E, Charlton B, Bowen DG, Koorey DJ, Shackel NA, McCaughan GW, Strasser SI. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World J Gastroenterol 2017; 23(15): 2763-2770